166 related articles for article (PubMed ID: 29783018)
1. Tumor inhibitory effects of intravesical Ganoderma lucidum instillation in the syngeneic orthotopic MB49/C57 bladder cancer mice model.
Yuen JWM; Mak DSY; Chan ES; Gohel MDI; Ng CF
J Ethnopharmacol; 2018 Sep; 223():113-121. PubMed ID: 29783018
[TBL] [Abstract][Full Text] [Related]
2. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
3. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.
Huang X; Yu HS; Chen Z; Li JL; Hu ZM; Gao JM
Chin J Cancer; 2010 Jun; 29(6):611-6. PubMed ID: 20507734
[TBL] [Abstract][Full Text] [Related]
4. Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice.
Zhao RL; He YM
J Ethnopharmacol; 2018 Jan; 210():287-295. PubMed ID: 28882624
[TBL] [Abstract][Full Text] [Related]
5. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
[TBL] [Abstract][Full Text] [Related]
6. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model.
Hegele A; Dalpke A; Heeg K; Barth P; Varga Z; Hofmann R; Olbert P
Tumour Biol; 2005; 26(5):274-80. PubMed ID: 16103747
[TBL] [Abstract][Full Text] [Related]
8. [A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].
Liang ZK; Zhang L; Hu ZM; Chen Z; Huang X; Shi XH; Tan WL; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):627-30. PubMed ID: 19403380
[TBL] [Abstract][Full Text] [Related]
9. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
10. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
11. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model.
Chade DC; Andrade PM; Borra RC; Leite KR; Andrade E; Villanova FE; Srougi M
Int Braz J Urol; 2008; 34(2):220-6; discussion 226-9. PubMed ID: 18462521
[TBL] [Abstract][Full Text] [Related]
12. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
13. Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S; Sathiyanadan K; La Rosa S; Polák L; Chevalier MF; Martel P; Hojeij R; Derré L; Haefliger JA; Jichlinski P; Nardelli-Haefliger D
Cancer Immunol Res; 2019 Apr; 7(4):621-629. PubMed ID: 30696629
[TBL] [Abstract][Full Text] [Related]
14. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
Xiao Z; Mak A; Koch K; Moore RB
BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
[TBL] [Abstract][Full Text] [Related]
15. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
[TBL] [Abstract][Full Text] [Related]
16. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy.
McAveney KM; Gomella LG; Lattime EC
Cancer Immunol Immunother; 1994 Dec; 39(6):401-6. PubMed ID: 8001028
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
[TBL] [Abstract][Full Text] [Related]
18. The differential immunological activities of Ganoderma lucidum on human pre-cancerous uroepithelial cells.
Yuen JW; Gohel MD; Ng CF
J Ethnopharmacol; 2011 Jun; 135(3):711-8. PubMed ID: 21501679
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models.
Weng CJ; Chau CF; Yen GC; Liao JW; Chen DH; Chen KD
J Agric Food Chem; 2009 Jun; 57(11):5049-57. PubMed ID: 19422227
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
